IL33 and psoriasis: The epithelium-derived cytokines, namely TSLP, IL-25 and IL-33 represent a new target for future therapies, especially in terms of itch control and, possibly, side-effects minimization, but not enough studies, especially in psoriasis, have been conducted in this direction.